Fentanyl Matrix in Lung Cancer Pain

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the usefulness of fentanyl matrix by assessing patients' satisfaction when administrating fentanyl matrix, a background pain treatment, and a breakthrough pain treatment to lung cancer patients who complain of pain. Fentanyl matrix is designed to deliver medication at a nearly constant amount per unit time into the body through the skin for 3 days (72 hours).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Korea, Ltd., Korea
• Treatments: Fentanyl

Criteria

Inclusion Criteria:

• Patients with histologically confirmed lung cancer, who complain of cancer pain

• Patients who are taking Ultracet, Tramadol, or Codeine (or Codeine combination drug) for cancer pain-relief purposes, but still complain of a pain level of 4 or above on the Numeric Rating Scale (NRS) during the past 24 hours: Ultracet 3 tablets/day, Tramadol 150 mg/day, Codeine 200 mg /day, or Codeine combination less than 3 capsules/day

• Patients who are able to communicate with the investigator about his/her pain

• Patients who use proper contraceptives during the study period if they are women of childbearing potential

• Patients whose life expectancy is 3 months or longer

• Patients who have signed an informed consent form

Exclusion Criteria:

• Patients participating in other clinical trials

• Patients with a history of hypersensitivity to opioid analgesics

• Patients with a history of drug abuse

• Patients who are unable to use a transdermal product due to skin disease

• Patient with a history of CO2 retention (e.g. chronic obstructive pulmonary disease)

• Patients who are receiving radiotherapy or chemotherapy when registering for the study or who plan to receive it during the study

• Patient who are pregnant or are of childbearing potential and not using contraceptives